Healius
Market Cap
AU$2.1b
Last Updated
2020/10/22 10:33 UTC
Data Sources
Company Financials +
Executive Summary
Healius Limited provides facilities and support services to independent general practitioners, radiologists, and other healthcare professionals in Australia. More Details
Rewards
Risk Analysis
Snowflake Analysis
Proven track record with mediocre balance sheet.
Similar Companies
Share Price & News
How has Healius's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: HLS has not had significant price volatility in the past 3 months.
Market Performance
7 Day Return
8.0%
HLS
-2.1%
AU Healthcare
0.3%
AU Market
1 Year Return
19.7%
HLS
4.0%
AU Healthcare
-5.4%
AU Market
Return vs Industry: HLS exceeded the Australian Healthcare industry which returned 4% over the past year.
Return vs Market: HLS exceeded the Australian Market which returned -5.4% over the past year.
Shareholder returns
| HLS | Industry | Market | |
|---|---|---|---|
| 7 Day | 8.0% | -2.1% | 0.3% |
| 30 Day | 8.7% | 2.4% | 6.3% |
| 90 Day | 18.6% | 5.3% | 3.7% |
| 1 Year | 21.1%19.7% | 6.0%4.0% | -2.1%-5.4% |
| 3 Year | 18.3%7.7% | 21.9%12.1% | 18.3%3.3% |
| 5 Year | 17.8%0.8% | 28.4%10.9% | 43.1%14.0% |
Price Volatility Vs. Market
How volatile is Healius's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 year ago | Simply Wall St
Why You Should Care About Healius Limited’s (ASX:HLS) Low Return On CapitalValuation
Is Healius undervalued compared to its fair value and its price relative to the market?
1.0%
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: HLS (A$3.76) is trading below our estimate of fair value (A$3.8)
Significantly Below Fair Value: HLS is trading below fair value, but not by a significant amount.
Price To Earnings Ratio
PE vs Industry: HLS is poor value based on its PE Ratio (32.5x) compared to the AU Healthcare industry average (29.8x).
PE vs Market: HLS is poor value based on its PE Ratio (32.5x) compared to the Australian market (21x).
Price to Earnings Growth Ratio
PEG Ratio: HLS is poor value based on its PEG Ratio (3.1x)
Price to Book Ratio
PB vs Industry: HLS is good value based on its PB Ratio (1.2x) compared to the AU Healthcare industry average (1.4x).
Next Steps
Future Growth
How is Healius forecast to perform in the next 1 to 3 years based on estimates from 10 analysts?
10.4%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: HLS's forecast earnings growth (10.4% per year) is above the savings rate (2.3%).
Earnings vs Market: HLS's earnings (10.4% per year) are forecast to grow slower than the Australian market (17.4% per year).
High Growth Earnings: HLS's earnings are forecast to grow, but not significantly.
Revenue vs Market: HLS's revenue (4.1% per year) is forecast to grow slower than the Australian market (4.6% per year).
High Growth Revenue: HLS's revenue (4.1% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: HLS's Return on Equity is forecast to be low in 3 years time (5.3%).
Next Steps
Past Performance
How has Healius performed over the past 5 years?
4.0%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: HLS has a large one-off gain of A$19.4M impacting its June 30 2020 financial results.
Growing Profit Margin: HLS's current net profit margins (4.5%) are higher than last year (3.7%).
Past Earnings Growth Analysis
Earnings Trend: HLS has become profitable over the past 5 years, growing earnings by 4% per year.
Accelerating Growth: HLS's earnings growth over the past year (25.4%) exceeds its 5-year average (4% per year).
Earnings vs Industry: HLS earnings growth over the past year (25.4%) exceeded the Healthcare industry -6.1%.
Return on Equity
High ROE: HLS's Return on Equity (3.7%) is considered low.
Next Steps
Financial Health
How is Healius's financial position?
Financial Position Analysis
Short Term Liabilities: HLS's short term assets (A$1.3B) exceed its short term liabilities (A$972.8M).
Long Term Liabilities: HLS's short term assets (A$1.3B) do not cover its long term liabilities (A$1.7B).
Debt to Equity History and Analysis
Debt Level: HLS's debt to equity ratio (43.2%) is considered high.
Reducing Debt: HLS's debt to equity ratio has reduced from 50.6% to 43.2% over the past 5 years.
Debt Coverage: HLS's debt is well covered by operating cash flow (40.7%).
Interest Coverage: HLS's interest payments on its debt are not well covered by EBIT (1.5x coverage).
Balance Sheet
Next Steps
Dividend
What is Healius's current dividend yield, its reliability and sustainability?
2.24%
Forecast Dividend Yield
Dividend Yield vs Market
Notable Dividend: Unable to evaluate HLS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate HLS's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if HLS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if HLS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: HLS is not paying a notable dividend for the Australian market.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of HLS's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
1.2yrs
Average management tenure
CEO
Malcolm Parmenter (65 yo)
3.08yrs
Tenure
AU$3,232,745
Compensation
Dr. Malcolm W. Parmenter, MB, BS, MAICD, has been the Managing Director and Chief Executive Officer at Healius Limited (formerly known as Primary Health Care Limited) since joined on September 06, 2017 & s ...
CEO Compensation Analysis
Compensation vs Market: Malcolm's total compensation ($USD2.30M) is above average for companies of similar size in the Australian market ($USD1.29M).
Compensation vs Earnings: Malcolm's compensation has increased by more than 20% in the past year.
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Director | 3.08yrs | AU$3.23m | 0.018% A$ 383.8k | |
| Chief Financial Officer | 1.17yrs | AU$1.41m | 0.0098% A$ 210.5k | |
| Chief Executive of Imaging | 5yrs | AU$1.34m | 0.0054% A$ 115.9k | |
| Chief Executive of the Pathology Division | 1.17yrs | AU$1.19m | 0.0026% A$ 55.3k | |
| Group Executive of People & Shared Services | 0.92yr | no data | no data | |
| Chief Executive of Medical Centre | 0.92yr | no data | no data | |
| CEO of Montserrat Day Hospitals | 0.92yr | no data | no data | |
| Company Secretary | 5.67yrs | no data | no data | |
| Additional Company Secretary | 1.17yrs | no data | no data | |
| Group Executive of Corporate Affairs | 5.25yrs | no data | no data | |
| 3yrs | AU$1.16m | no data |
1.2yrs
Average Tenure
Experienced Management: HLS's management team is not considered experienced ( 1.2 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| MD, CEO & Director | 3.08yrs | AU$3.23m | 0.018% A$ 383.8k | |
| Independent Non-Executive Director | 8.17yrs | AU$163.56k | 0.0026% A$ 54.9k | |
| Non-Executive Director | 5.17yrs | AU$161.82k | 0.0089% A$ 191.8k | |
| Independent Non-Executive Director | 9.92yrs | AU$147.57k | 0.0065% A$ 139.5k | |
| Chairman | 2.25yrs | AU$277.50k | 0.012% A$ 264.7k | |
| Independent Non-Executive Director | 2.17yrs | AU$157.52k | 0.0024% A$ 51.6k |
4.1yrs
Average Tenure
63.5yo
Average Age
Experienced Board: HLS's board of directors are considered experienced (4.1 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Healius Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Healius Limited
- Ticker: HLS
- Exchange: ASX
- Founded: 1994
- Industry: Health Care Services
- Sector: Healthcare
- Market Cap: AU$2.143b
- Shares outstanding: 623.01m
- Website: https://www.healius.com.au
Number of Employees
Location
- Healius Limited
- 203 Pacific Highway
- Level 6
- St Leonards
- New South Wales
- 2065
- Australia
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| HLS | ASX (Australian Securities Exchange) | Yes | Ordinary Shares | AU | AUD | Jul 1998 |
| PGZ | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Jul 1998 |
| HLS | CHIA (Chi-X Australia) | Yes | Ordinary Shares | AU | AUD | Jul 1998 |
Biography
Healius Limited provides facilities and support services to independent general practitioners, radiologists, and other healthcare professionals in Australia. The company operates through three segments: Pa ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2020/10/22 10:33 |
| End of Day Share Price | 2020/10/22 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2020/06/30 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.